An open-label, single-dose study to evaluate the pharmacokinetics and safety of DS-8500a in Japanese subjects with varying degrees of hepatic or renal function
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2017
At a glance
- Drugs DS-8500 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 25 Jan 2017 Status changed from recruiting to completed.
- 25 Jul 2016 Status changed from not yet recruiting to recruiting.
- 14 Jun 2016 New trial record